Abstract:591 Background: The incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are increasing worldwide. Surgery remains the only curative modality. Because of limited data on patterns of recurrence, real-world surveillance practices and duration vary widely. In 2018, the Commonwealth Neuroendocrine Tumour Research Collaboration (CommNETs) published consensus surveillance guidelines for patients with completely resected GEP-NETs. Our aim was to assess adherence to the CommNETs guidelines for surveillance practices for this patient population at our center. Methods: We conducted a retrospective cohort study of patients with GEP-NETs seen for a new patient appointment at Princess Margaret Cancer Centre (PMCC) from 2019-2022. Patients were included if they had a completely resected GEP-NET and followed on surveillance at our center. Demographic and tumor characteristics, surveillance practices, and clinical outcomes were abstracted. Summary statistics and a descriptive comparison of surveillance practices were completed. Results: Out of the 374 new patient appointments, 87 met the inclusion criteria. The main reasons for exclusion were metastatic disease at presentation (n=128), primary tumor not resected (n=58), and patients not followed at PMCC (n=49) so their surveillance practices cannot be determined from our records. The primary tumor sites were pancreatic (n=50, 57%), appendiceal (n=15, 17%), small bowel (n=11, 13%), rectal (n=10, 12%), and colon (n=1, 1%). Thirty-eight patients (44%) had stage 1 disease, 21 patients (24%) had stage 2, and 28 patients (32%) had stage 3. Forty-six patients (53%) had a WHO tumor grade of 1, 36 patients (41%) had grade 2, and 5 patients (6%) had grade 3. The median duration of follow-up was 18.2 months. Adherence to ordering the recommended surveillance investigations was 23% (20/87). Within the adherent cases, there was a higher number of appendiceal, WHO grade 1, and stage 1 tumors. Sixty-six patients (76%) had at least one test that was not recommended by the guidelines. The most frequent unnecessary tests were CT chest in all patient groups and CT pelvis in pancreatic NETs (Table). Six patients were lost to follow up and none discharged from surveillance. Conclusions: Adherence to the CommNETs consensus guidelines was low at our center, suggesting the guidelines had a minor impact on surveillance practices and providing an area for improvement in process of care and resource utilization. [Table: see text]

Management & surveillance of rectal neuroendocrine tumours: a single‐centre retrospective analysis

Pathological Characteristics, Management, and Prognosis of Rectal Neuroendocrine Tumors: A Retrospective Study from a Tertiary Hospital

Endoscopic submucosal dissection for rectal neuroendocrine tumours: A multicentric retrospective study

Risk Factors and Clinical Outcomes of Incomplete Endoscopic Resection of Small Rectal Neuroendocrine Tumors in Southern China: a 9-Year Data Analysis

An Update on the Management of Rectal Neuroendocrine Neoplasms

Quality of surveillance in patients with completely resected gastroenteropancreatic neuroendocrine tumors.

Long-term Outcomes of 1–2 Cm Rectal Neuroendocrine Tumors after Local Excision or Radical Resection: A Population-Based Multicenter Study

Optimization of endoscopic treatment strategies for R0 resection of rectal neuroendocrine tumors smaller than 10mm

When is neoadjuvant chemotherapy indicated in rectal neuroendocrine tumors? An analysis of the National Cancer Database

Endoscopic treatments for rectal neuroendocrine tumors: a systematic review and network meta-analysis

Clinical significance of positive resection margin for patients with rectal neuroendocrine tumors within 20 mm following initial endoscopic resection: A multi-center study

Multivariable Analysis for Complete Resection Rate of 10-20 Mm Non-Metastatic Rectal Neuroendocrine Tumors: a Retrospective Clinical Study

Clinical and pathological characteristics and prognosis of 132 cases of rectal neuroendocrine tumors

Optimization of Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection Strategies for Rectal Neuroendocrine Tumors Within 20 mm

The meaning of R1 resection after endoscopic removal of gastric, duodenal and rectal neuroendocrine tumors

Watch-an-wait strategy for multiple rectal neuroendocrine tumors with widespread invasion

Multiple rectal neuroendocrine tumors: An analysis of 15 cases and literature review

Early diagnosis and treatment of gastrointestinal neuroendocrine tumors.

Clinical outcomes after endoscopic resection and the risk of lymph node metastasis in rectal neuroendocrine tumors: a single-center retrospective study

Impact of grade on workup of rectal neuroendocrine tumors: a retrospective cohort study

Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS)